AREA PRESCRIBING COMMITTEE – Birmingham, Sandwell, Solihull and environs

Decision Making Support Tool

The following document supports the committee to consider formulary applications against defined criteria.

Formulary application reference:	APCBSSE/0022
Drug name and formulations:	Magnaspartate ®

Criteria	***Example***	**Committee Consensus**
Patient Safety	*Potential for abuse, toxicity, significant drug interactions*	No potential for abuse. Main side effect is diarrhoea at high doses. Risk of overdose is low unless renal function impaired. Requires monitoring.
Clinical effectiveness	*Established licensed product*	Only licensed product; other products are classed as food supplements.
Strength of evidence		No head to head clinical trial. Small retrospective study involving 4 patients.
Cost effectiveness or resource impact	*£*	Unlicensed products incur higher acquisition costs than licensed Magnaspartate® especially in primary care. Some unlicensed magnesium specials are included in the Drug Tariff.
Place of therapy relative to available treatments	*1/2nd tier*	First line for primary care management of short bowel syndrome.
National guidance and priorities	*NICE, MTRAC*	None
Local health priorities	*CCG views*	CCG supported
Equity of access	*Equality assessment*	No issue
Stakeholder views	*Define wider groups to be engaged*	N/A
Implementation requirements	*Requires, RICAD ESCA etc.*	None

Decision Summary

Resubmission is recommended to complete the	

information to enable a decision:	
Not approved and rationale:	
Formulary status (RAG) and rationale	Approved as AMBER – Specialist initiation or recommendation. Discharge summary should recommend use of licensed product.
Implementation requirements:	
Implementation monitoring:	